ClinicalTrials.gg
Active, not recruitingNCT06867757TRAC-PainUpdated Aug 20, 2026

Targeted Realtime Assessment of Chronic Pain in Youth

An observational study in Chronic Pain and Musculoskeletal Pain, sponsored by Stanford University. Active, not recruiting at 1 site in United States. Open to participants aged 14 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Stanford University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
14 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Chronic Pain by Stanford University — 14 open to participants now, 18 under way, 1 of them phase 3. Chronic Pain · Stanford University.

Planned enrollment
3rd of 10
500 · median 259
Started
2025
with 2 others
Observational
10 of 47
3 open now
Primary completion
2026-11
later than 3 of 17 live
Registered
41st of 47
by date

Among the 47 studies in Chronic Pain by Stanford University, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2025, is one of 10 observational ones, reaches primary completion later than 3 of the 17 other live ones, and was the 41st registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

14 of the 47 studies in Chronic Pain by Stanford University are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 14 Years to 24 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Chronic Pain by Stanford University, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the feasibility and acceptability of using wearable digital health technology for continuous monitoring of physiological, sleep, and physical activity data in adolescents with chronic musculoskeletal (MSK) pain. This research aims to develop objective digital endpoints of the pain experience to improve diagnosis, prevention, and treatment outcomes.

Read the detailed description

Up to 5% of adolescents (\~3.5 million in the US alone) suffer from high-impact chronic musculoskeletal (MSK) pain, affecting quality of life, school attendance, mood, and family function, and posing a significant economic burden of $19.5 billion annually in the US. A substantial proportion of these youths continue to suffer from pain into adulthood. Chronic MSK pain is characterized by a complex biological response, including physiological disturbances in cognition, sleep, and energy levels (fatigue), and is associated with impairments in both physical and emotional function. The chronic pain experience fluctuates over time with intra- and inter-daily variations and the occurrence of pain flares, contributing to unpredictability, uncertainty, and greater impairment.

Current gold standard self-report assessments are burdensome and fail to provide comprehensive, reliable measures of the pain experience due to inherent recall bias. A potential solution lies in the widespread adoption of digital health technologies, particularly wearable devices, which offer continuous monitoring of physiological, sleep, and physical activity data. This approach can yield unprecedented insights into individual health, informing diagnosis, prevention, monitoring, and treatment.

Through artificial intelligence (AI) and machine learning (ML), several groundbreaking digital biosignatures of human health have been developed by the research team, including those for glucose variability, preterm birth, panic attacks, fall risk, and surgical recovery. This real-time, personalized approach not only empowers patients but also enables healthcare providers to make more informed decisions, optimizing treatment strategies and improving outcomes. Despite these advancements, less than half of adolescents with chronic MSK pain who undergo pain treatment experience meaningful improvement.

The scientific rationale of this proposal is to overcome the limitations of self-report by integrating precise physiological, sleep, and physical activity measures from wearable devices with AI/ML to develop and validate a monitoring digital biosignature of the individual pain experience in youth with MSK pain. This biosignature will monitor the pain experience, track its progression, assess responses to interventions, and evaluate impacts on quality of life.

The research team is well positioned to execute these aims with: (1) a diverse, highly skilled team with expertise in digital technology, AI/ML, digital endpoint development, and clinical trials, alongside clinical expertise in chronic pain in youth and lived experience from patients, caregivers, and pain advocacy groups; (2) a secure, scalable, centralized, and standardized digital data collection, processing, and storage system; and (3) cutting-edge preliminary data supporting the capability to develop this digital health biosignature.

UG3/Discovery Phase: The research team will enroll up to 500 youth (ages 14-24) with chronic MSK pain, capturing continuous physiological (heart, respiratory), sleep, and physical (activity level, mobility, gait) activity metrics via wearables. Repeated intra-daily self-reports of the pain experience (pain interference, pain intensity, fatigue, mood, stress, pain flares) will be collected over 12 weeks. For a subset, data from physical and social stress tasks will also be gathered. The aim is to assess feasibility and relevance, develop a digital biosignature of the pain experience, and prepare for the UH3 phase through outreach and collaboration. Consultations with individuals with lived experience, those experiencing health disparities, and the FDA will ensure the relevance and acceptability of the biosignature and promote recruitment of underrepresented youth, coupled with scalability for clinical use.

UH3/Validation Phase: The research team will enroll up to 400 diverse youth with chronic MSK pain, capturing wearable and self-reported pain experience metrics over 12 weeks: a 4-week baseline followed by 8 weeks of abnormal reading-triggered alerts. The aim of this phase is to clinically validate the digital biosignature of the pain experience, and evaluate the accuracy and potential of an enhanced wellness alert system.

Significance and Clinical Impact: The successful development and validation of digital endpoints for the pain experience are crucial for advancing pain management. These endpoints promise to improve therapeutic development by providing robust, objective measures of treatment response. The outcomes of this study will be foundational for seeking regulatory approval for the commercialization of the associated software or for disseminating open-source analysis packages for future clinical trials.

03

Conditions studied

  • Chronic Pain
  • Musculoskeletal Pain
04

Who can participate

Ages eligible
14 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

14 - 24 year old adolescents with chronic musculoskeletal pain

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has musculoskeletal pain in 1 or more anatomic regions.
  • Pain persists for > 3 months.
  • Pain is associated with significant distress or life interference.

Exclusion criteria

Exclusion Criteria:

  • Significant cognitive impairment (e.g., unable to communicate)
  • Hospitalization in the past 30 days for something other than their pain condition
  • Currently undergoing treatment for cancer
  • Reports only headache, orofacial, or visceral pain
  • Currently pregnant or think you might become pregnant in the next 3 months
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • TRAC-Pain Cohort

    For 12 weeks, participants will wear a smartwatch for continuous physiological, sleep, and physical activity monitoring, and complete daily self-reported surveys on pain, mood, and stress. At the end of the study, participants will complete a stress task (Trier Social Stress Task) and a functional task (Sit-to-Stand Test) along with a feedback interview.

06

What researchers measure

Primary outcomes

  1. Pain, Enjoyment of Life, and General Activity (PEG) Scale

    The PEG scale, a subset of the Brief Pain Inventory (BPI), evaluates pain intensity and its impact on enjoyment of life and general activity using a ranked scale (score 0 = "no interference" to 10 = "highest level of interference") with a higher score reflecting greater disruption in daily functioning.

    Time frame: Daily from baseline to discharge, for a duration of 12 weeks

Secondary outcomes

  1. Numeric Rating Scale (NRS) of Present Pain

    The Numeric Rating Scale (NRS) for Present pain assesses the intensity of current pain using a ranked scale (0 = "no pain" to 10 = "the worst possible pain") with a higher score reflecting greater pain severity.

    Time frame: Daily from baseline to discharge, for a duration of 12 weeks

  2. Numeric Rating Scale (NRS) Fatigue

    The Numeric Rating Scale (NRS) for Fatigue measures the level of fatigue experienced using a ranked scale (0 = "no fatigue" to 10 = "the most extreme fatigue") with a higher score indicating greater exhaustion.

    Time frame: Daily from baseline to discharge, for a duration of 12 weeks

  3. Numeric Rating Scale (NRS) Stress Level

    The Numeric Rating Scale (NRS) for Stress Level evaluates the severity of stress using a ranked scale (0 = "no stress" to 10 = "the highest level of stress") with a higher score reflecting increased stress intensity.

    Time frame: Daily from baseline to discharge, for a duration of 12 weeks

  4. Numeric Rating Scale (NRS) Activity Level

    The Numeric Rating Scale (NRS) for activity level assesses a person's level of physical activity using a ranked scale (0 = "no activity" to 10 = "the highest possible level of activity") with a higher score reflecting greater engagement in physical activity.

    Time frame: Daily from baseline to discharge, for a duration of 12 weeks

  5. Numeric Rating Scale (NRS) Sleep Quality

    The Numeric Rating Scale (NRS) for Sleep Quality evaluates the quality of sleep using a ranked scale (0 = "the worst possible sleep quality" to 10 = "the best possible sleep quality") with a higher score reflecting better sleep quality.

    Time frame: Daily from baseline to discharge, for a duration of 12 weeks

Other outcomes

  1. Adolescent Sleep Wake Scale - Short Form (ASWS-SF)

    The Adolescent Sleep Wake Scale - Short Form (ASWS-SF) evaluates sleep patterns and quality in adolescents using a ranked scale (0 = "worst possible sleep quality" to 10 = "best possible sleep quality"), with a higher score reflecting better sleep quality.

    Time frame: Baseline and Discharge (at 12 weeks)

  2. Adverse Events

    The Adverse Events scale monitors for any adverse effects related to the intervention, tracking their frequency and severity, with higher values indicating a greater number or severity of adverse events.

    Time frame: As needed, from baseline to discharge, for a duration of 12 weeks

  3. Brief Pain Inventory Short Form (BPI-SF)

    The Brief Pain Inventory Short Form (BPI-SF) evaluates pain severity and its interference with daily functioning using a 10-point Likert scale (0 = "no pain/interference" to 10 = "worst possible pain/interference"), with a higher score indicating greater pain severity and disruption.

    Time frame: Baseline and Discharge (at 12 weeks)

  4. Child Activity Limitations Interview-9 (CALI-9)

    The Child Activity Limitations Interview-9 (CALI-9) assesses activity limitations due to pain in children and adolescents using a ranked scale (0 = "no activity limitations" to 10 = "unable to engage in any activities"), with a higher score reflecting greater restrictions in daily activities.

    Time frame: Baseline and Discharge (at 12 weeks)

  5. Generalized Anxiety Disorder-2 (GAD-2)

    The Generalized Anxiety Disorder-2 (GAD-2) screens for generalized anxiety symptoms using two questions, scored on a scale from 0 to 6 (0 = "no anxiety symptoms" to 6 = "severe anxiety symptoms"), with a higher score indicating greater anxiety severity.

    Time frame: Daily from baseline to discharge, for a duration of 12 weeks

  6. Healthcare Use Diary

    The Healthcare Use Diary records the frequency and type of healthcare services used, with higher values indicating greater healthcare utilization.

    Time frame: As needed, from baseline to discharge, for a duration of 12 weeks

  7. McGill Pain Questionnaire 2 (SF-MPQ-2)

    The McGill Pain Questionnaire 2 (SF-MPQ-2) measures the sensory, affective, and evaluative dimensions of pain using a ranked scale (0 = "no pain" to 10 = "worst possible pain"), with a higher score indicating more severe pain experiences.

    Time frame: Baseline

  8. National Institute on Drug Abuse-2 (NIDA-2)

    The National Institute on Drug Abuse-2 (NIDA-2) screens for substance use risk and behaviors using a 0 to 6 scale (0 = "no substance use risk" to 6 = "highest substance use risk"), with a higher score indicating increased risk.

    Time frame: Baseline and Discharge (at 12 weeks)

  9. Net Promoter Score (NPS)

    The Net Promoter Score (NPS) measures the likelihood of recommending the intervention to others using a scale from 0 to 10 (0 = "not at all likely to recommend" to 10 = "extremely likely to recommend"), with a higher score indicating greater satisfaction.

    Time frame: Discharge (at 12 weeks)

  10. Pain Catastrophizing Scale - Children (PCS-C)

    The Pain Catastrophizing Scale - Children (PCS-C) assesses negative thoughts and feelings related to pain using six questions, scored from 0 to 24 (0 = "no catastrophizing" to 24 = "highest level of catastrophizing"), with a higher score indicating greater pain-related distress

    Time frame: Baseline and Discharge (at 12 weeks)

  11. Pain Flare

    The Pain Flare scale tracks the occurrence and severity of pain flare-ups using a ranked scale (0 = "no pain flare" to 10 = "worst possible pain flare"), with a higher score reflecting more intense and frequent pain exacerbations

    Time frame: As needed, from baseline to discharge, for a duration of 12 weeks

  12. Pain Wellness Behaviors

    The Pain Wellness and Daily Events scale logs daily wellness activities and notable events that might affect pain levels, providing insight into patterns and triggers.

    Time frame: As needed, from baseline to discharge, for a duration of 12 weeks

  13. Pain Wellness and Daily Events

    The Pain Wellness Behaviors scale assesses engagement in behaviors that promote pain management and overall wellness using a ranked scale (0 = "no engagement in wellness behaviors" to 10 = "consistent engagement in wellness behaviors"), with a higher score reflecting greater adherence to positive health behaviors.

    Time frame: As needed, from baseline to discharge, for a duration of 12 weeks

  14. Patient Global Impression of Change (PGIC)

    The Patient Global Impression of Change (PGIC) measures the patient's overall perception of improvement using a ranked scale (0 = "no improvement" to 10 = "greatest possible improvement"), with a higher score indicating greater perceived positive change.

    Time frame: Baseline and Discharge (at 12 weeks)

  15. Patient Health Questionnaire-2 (PHQ-2)

    The Patient Health Questionnaire-2 (PHQ-2) screens for depressive symptoms using two questions, scored from 0 to 6 (0 = "no depressive symptoms" to 6 = "severe depressive symptoms"), with a higher score indicating greater severity of depressive symptoms.

    Time frame: Daily from baseline to discharge, for a duration of 12 weeks

  16. Patient-Reported Outcomes Measurement Information System Fatigue (PROMIS Fatigue)

    The Patient-Reported Outcomes Measurement Information System Fatigue (PROMIS-Fatigue) evaluates the frequency and intensity of fatigue using a ranked scale (0 = "no fatigue" to 10 = "most severe fatigue"), with a higher score indicating greater fatigue severity.

    Time frame: Baseline and Discharge (at 12 weeks)

  17. Patient-Reported Outcomes Measurement Information System Physical Function Short Form 8c (PROMIS Physical Function)

    The Patient-Reported Outcomes Measurement Information System Physical Function Short Form 8c (PROMIS Physical Function) measures physical functioning capabilities and limitations using a ranked scale (0 = "severe limitations" to 10 = "no limitations"), with a higher score indicating better physical function.

    Time frame: Baseline and Discharge (at 12 weeks)

  18. Patient-Reported Outcomes Measurement Information System Stress Experiences Short Form 4a (PROMIS Stress)

    The Patient-Reported Outcomes Measurement Information System Stress Experiences Short Form 4a (PROMIS Stress) assesses perceived stress levels over the past seven days using a ranked scale (0 = "no stress" to 10 = "highest level of stress"), with a higher score indicating greater stress.

    Time frame: Baseline and Discharge (at 12 weeks)

  19. Positive and Negative Affect Schedule - 10 Item (PANAS-10)

    The Positive and Negative Affect Schedule - 10 Item (PANAS-10) measures both positive and negative affect using ten items, scored separately from 0 to 50 (0 = "no affect" to 50 = "highest affect intensity"), with a higher score reflecting greater emotional intensity.

    Time frame: Daily from baseline to discharge, for a duration of 12 weeks

  20. Social Determinants of Health (SDOH)

    The Social Determinants of Health (SDOH) scale assesses factors such as socioeconomic status, education, and environment that influence health outcomes, with a higher score indicating greater social risk factors.

    Time frame: Baseline

  21. Theoretical framework of acceptability (TFA)

    The Theoretical Framework of Acceptability (TFA) scale evaluates participant perceptions of an intervention's acceptability using a ranked scale (0 = "not acceptable" to 10 = "highly acceptable"), with a higher score reflecting greater acceptance and perceived usefulness.

    Time frame: Discharge (at 12 weeks)

  22. Usage metrics

    The Usage Metrics scale assesses participant engagement with the intervention by tracking hours of smartwatch wear, percentage of completed surveys, and check-ins, with higher values indicating greater adherence and participation.

    Time frame: Daily from baseline to discharge, for a duration of 12 weeks

  23. World Health Organization Quality of Life 2 Item (WHOQOL-2)

    The World Health Organization Quality of Life 2 Item (WHOQOL-2) measures overall quality of life and general health using a ranked scale (0 = "worst quality of life" to 10 = "best quality of life"), with a higher score indicating better quality of life and health perception.

    Time frame: Baseline and Discharge (at 12 weeks)

  24. Pediatric Pain Screening Tool (PPST)

    The Pediatric Pain Screening Tool (PPST) is a 9-item self-report measure designed to assess both physical and psychosocial aspects of pain in youth

    Time frame: Baseline and discharge (at 12 weeks)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Robust individual level data will be available to share, not just group level data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Nov 2026, 21 months after the start.

Of 337 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's planned 21 months is below that.

Counting every sponsor, half of 363 studies reached it within 24 months; a quarter within 12 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 10, 2025
StartActual
Feb 28, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06867757
Responsible party
Laura E Simons (Professor of Anesthesiology, Perioperative, and Pain Medicine (Pediatric), Stanford University) — Principal investigator
First posted
Mar 10, 2025
Start date
Feb 28, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Aug 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion